News | January 28, 2023
Aarti Drugs Q3 FY23 revenue grows 4%
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
The company will respond to these observations within the stipulated time period.
Greenko ZeroC will supply Carbon Free Energy and enable Green Hydrogen along with its various chemical derivatives.
Surana is a chartered accountant with an all-India rank.
Total investment envisaged in this project stands at up to Rs 70 crore
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
The new production line is equipped with the latest advanced manufacturing system to produce quality products of Alkaloids & APIs used in a wide range of pharmaceutical applications
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
The pre-approval inspection of USFDA was completed successfully with ZERO 483 observation of the manufacturing facilities of Bajaj Healthcare Limited
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
